You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 793 Combined administration of the dual A2aR/A2bR antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Combination Immunotherapies
793 Combined administration of the dual A2aR/A2bR antagonist etrumadenant with a reduced chemotherapy regimen leads to enhanced tumor efficacy and survival

 

Online download statistics by month:

Online download statistics by month: December 2023 to June 2025

AbstractFullPdf
Dec 20237006
Jan 20242704
Feb 20242003
Mar 202420010
Apr 20243402
May 20243006
Jun 20242504
Jul 202424011
Aug 20241401
Sep 20243207
Oct 20241507
Nov 20241205
Dec 20245606
Jan 20251106
Feb 2025406
Mar 2025006
Apr 2025001
May 2025006
Jun 2025004
Total3940101